Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor: A Pilot Study on Comparable Efficacy in the Treatment of Gastroesophageal Reflux-Related Cough

Acid inhibitors have been considered in treating gastroesophageal reflux-related cough (GERC). Compared to proton pump inhibitors (PPIs), potassium -competitive acid blockers (P -CABs) have more potent and durable effects on anti -acid secretion. However, whether vonoprazan and esomeprazole have different therapeutic effects on GERC remains unknown. Patients diagnosed with GERC were enrolled in our study and randomly treated with vonoprazan (20 mg, once daily, P -CAB) or esomeprazole (20 mg, twice daily, PPI) for two months. A prokinetic agent was also administered. Patients were followed up once a month. Cough severity visual analogue scale (VAS) was measured as the primary outcome, while cough symptom score (CSS) and scores for cough -related quality -of -life or reflux-related symptoms were the secondary endpoints. A total of 50 patients completed the study, with 25 patients in each group. P -CAB and PPI groups showed similar decreases in cough severity VAS and CSS scores after the 2 -month treatment (all P < 0.001). For quality -of -life, the Leicester Cough Questionnaire (LCQ) score increased significantly from baseline in both groups, but the P -CAB group had greater improvement and a higher LCQ score in month 2 (all P <= 0.05). For reflux-related symptoms, the Hull Airway Reflux Questionnaire (HARQ) score declined substantially over time in the P -CAB group, while the reflux symptom index (RSI) score decreased in both groups. The P -CAB group tended to have a lower HARQ (P = 0.051) and RSI (P = 0.069) scores in month 2. In conclusion, vonoprazan may be comparable to esomeprazole in cough symptom relief in GERC during the 2 -month treatment period, but possibly provides better gains on classic reflux symptoms and quality -of -life. The long-term efficacy of P -CABs on GERC may be worth further exploration.